PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New cocktail of three drugs shows promise for tough brain cancer
Disease control CompletedThis early-phase trial tested a combination of three drugs—ibrutinib, rituximab, and lenalidomide—in 25 patients with central nervous system lymphoma that had returned or not responded to prior treatment. The main goal was to find the safest dose of ibrutinib when given with the …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for brain cancer patients: drug may stop relapse
Disease control CompletedThis study tested whether the drug nivolumab can safely prevent primary central nervous system lymphoma (PCNSL) from coming back. It included 14 people who still had signs of tumor DNA in their spinal fluid after finishing their first chemotherapy. The goal was to see if nivoluma…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Liver function may change how tirabrutinib acts in the body
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC